Physicians and researchers from the University of Florida are participating in the American Society of Clinical Oncology (ASCO) Annual Meeting held on June 3-7, 2022 in Chicago, IL.
The ASCO Annual Meeting is one of the largest gatherings of medical professionals in the world. It brings together more than 25,000 oncology professionals from a broad range of specialties for five days of cutting-edge scientific presentations. The full conference program is available here.
This year’s program will feature over 200 sessions complementing the meeting’s theme: “Advancing Equitable Cancer Care Through Innovation.”
The names of UF Health Cancer Center collaborators are in bold below.
Abstracts + Presentations
- Jesus Fabregas, M.D. with Ilyas Sahin, M.D., Sherise Rogers, M.D., Brian Ramnaraign, M.D., Ibrahim Nassour, M.D., Steven Hughes, M.D., and Thomas George, M.D.
Impact of metastasectomy for extrahepatic disease in stage IV colon cancer: A retrospective cohort NCDB analysis.
- Sherise Rogers – with Brian Ramnaraign, M.D., Kathryn Hitchcock, M.D., Ph.D., Steven Hughes, M.D., Ji-Hyun Lee, DrPH, Ibrahim Nassour, M.D., Jesus Fabregas, M.D., Ryan Thomas, Ilyas Sahin, M.D., Carmen Allegra, M.D., David DeRemer, PharmD, and Thomas George, M.D.
A phase II, open-label, pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.
- Thomas George – with Jesus Fabregas, M.D. and Carmen Allegra, M.D.
NSABP FC-12: A single-arm, phase II study to evaluate treatment with gevokizumab in patients with stage II/III colon cancer who remain ctDNA+ after curative surgery and adjuvant chemotherapy.
- Thomas George – with Ji-Hyun Lee, DrPH, David DeRemer, PharmD, Jonathan Chatzkel, Brian Ramnaraign, M.D., Sherise Rogers, M.D., Merry Jennifer Markham, Karen Daily, Martina Murphy, Aaron Franke, Stephen Staal, Julia Close, Dennie Jones, and Carmen Allegra, M.D.
Results of a phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response pathway deficient neoplasms.
- Bently Doonan – with Duane Mitchell, M.D., Ph.D.
CA-4948 for the treatment of melanoma brain metastasis.
- Ellery Altshuler, M.D. – with Sherise Rogers, M.D., Ibrahim Nassour, M.D., Brian Ramnaraign, M.D., Ilyas Sahin, M.D., Aaron Franke, M.D., Thomas George, M.D., Steven Hughes, M.D., and Jesus Fabregas, M.D.
Prognostic value of CA 19-9 and carcinoembrionic antigen (CEA) in duodenal adenocarcinoma (DA): An institutional retrospective cohort study.
- Andrea Riner, M.D. – with Thomas George, M.D.
Use of modernized eligibility criteria in pancreatic cancer clinical trials.
- Grace Ann Hanvey, M.S. – with Dennie Jones, M.D., Frederic Kaye, M.D., Merry Jennifer Markham, M.D., and Deidre Pereira, Ph.D.
Effects of a yoga intervention on distress indicators among diverse women with gynecologic, gastrointestinal, and thoracic cancers.
- Kelsey Bacharz, M.A. – with Merry Jennifer Markham, M.D., Frederic Kaye, M.D., Dennie Jones, M.D., and Deidre Pereira, Ph.D.
Feasibility and acceptability of a yoga intervention for distress in women with gynecologic, gastrointestinal, or thoracic cancer.
- Anjelica Body – with David Tran, M.D., Ph.D., Maryam Rahman, M.D., Ashley Ghiaseddin, M.D., and Deidre Pereira, Ph.D.
Feasibility and acceptability of measuring psychosocial outcomes for primary brain tumor patients and caregivers in a neuro-oncology clinical setting.
- Caio Max Sao Pedro Rocha Lima, M.D. – with Thomas George, M.D.
Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.
- Nusayba Ali Bagegni, M.D. – with Karen Daily, D.O.
A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC).
- John Krauss, M.D. – with Thomas George, M.D., and Carmen Allegra, M.D.
NSABP FC-10: A phase Ib study of pembrolizumab (pembro) in combination with pemetrexed (pem) and oxaliplatin (oxali) in patients with chemo-refractory metastatic colorectal cancer (mCRC).
- Arvind Dasari, M.D. – with Thomas George, M.D.
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.
- Mohamed Salem, M.D. – with Thomas George, M.D., and Carmen Allegra, M.D.
NSAB C-14: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease.
- Mohamed Salem, M.D. – with Thomas George, M.D.
Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC).
- Alice Sims – with Zeina Al-Mansour, M.D.
A phase 1b/2 study of TP-0903 and decitabine targeting mutant TP53 and/or complex karyotype in patients with untreated acute myeloid leukemia ≥ age 60 years: Phase 1b interim results.
- Samuel Jacobs, M.D. – with Thomas George, M.D., and Carmen Allegra, M.D.
NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with “quadruple wild-type” metastatic colorectal cancer (mCRC) based on HER2 status.
- Mohamed Salem, M.D. – with Thomas George, M.D.
Comparative analysis of microsatellite instability-high (MSI-H) BRAF V600E-mutated versus MSI-H BRAF wild type colorectal cancers (CRC), including tumor microenvironment (TME), associated genomic alterations, and immunometabolomic biomarkers.
- Mark Dickson, M.D. – with Martina Murphy, M.D.
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.
- Min Jee Lee, Ph.D. – with Ramzi Salloum, Ph.D.
Cost-related medication nonadherence and cost-saving strategies among Native Hawaiian and Pacific Islander cancer survivors.
- Romain Cohen, M.D., Ph.D. – with Thomas George, M.D.
Using T stage to predict outcomes of adjuvant oxaliplatin (OX)-based chemotherapy (CT) in stage III colon cancer (CC): An ACCENT pooled analysis.
Oncology Division Chiefs & Departments Chair’s Breakfast
Time: Sat, Jun 4 | 8:30 a.m.-10:30 a.m.
Chair: Merry Jennifer Markham, M.D.
Track(s): Professional Development and Education Advanced
The Evolving Landscape of Social Media: What Should the Health Professional Know?
Location: Location: E253b
Time: Sat, June 4 | 4:00 p.m.-4:20 p.m.
Speaker: Merry Jennifer Markham, M.D.
Track(s): Professional Development and Education Advances | Ethics